Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Charles River Labs (CRL) PT Raised to $84 at UBS Following Strong 4Q Results
February 15, 2017 9:31 AM ESTUBS analyst Jonathan Groberg maintains Sell rating and raises price target on Charles River Laboratories International (NYSE: CRL) to $84 (from $78), as the company announced revenue and EPS figures above consensus projections.
Groberg comments, "CRL reported 4Q16 results with reported revenue of $467m,... More
Charles River Labs (CRL) PT Raised to $104 at Jefferies Following Strong 4Q Results
February 15, 2017 8:11 AM ESTJefferies analyst David Windley reiterates Buy rating and raises price target on Charles River Laboratories (NYSE: CRL), as the company reported 2016 fourth quarter revenue and EPS above consensus.
Windley comments, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments.... More
